- Zydus has received final approval from the USFDA to market Dapagliflozin Tablets in the strengths of 5 mg and 10 mg (USRLD: Farxiga).
- Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Dapagliflozin also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalization for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys.
- The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
Zydus receives final approval from USFDA for Dapagliflozin Tablets
Related Posts
Leave a Reply
Recent News
